Phase I trial of SCY 635 in patients with genotype 1 hepatitis C.

Trial Profile

Phase I trial of SCY 635 in patients with genotype 1 hepatitis C.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2010

At a glance

  • Drugs SCY 635 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors SCYNEXIS
  • Most Recent Events

    • 16 Apr 2010 Resistance results presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL), according to a SCYNEXIS media release.
    • 26 Apr 2009 Results reported at the 44th Annual Meeting of the European Association for the Study of the Liver.
    • 25 Apr 2009 Results were presented in a media release, and at the 44th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top